To mitigate potential risk of toxicity to normal cells, SDMA is being evaluated as a biomarker of PRMT5 activity in human clinical trials evaluating the PRMT5 inhibitors compounds (JNJ-64619178, GSK3326595, and PRT543) in patients with relapsed/refractory non-Hodgkin lymphoma or advanced solid tumors (NCT03573310, NCT02783300, and NCT03886831). This evidence concerns the gene PRMT5 and non-Hodgkin lymphoma.